Intralesional Talimogene Laherparepvec Immunotherapy for Melanoma: A Case Study

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Advanced melanoma presents significant clinical challenges, with limited therapeutic options beyond surgery for localized disease.
• Oncolytic virotherapy, using engineered viruses to target cancer cells, is an emerging treatment modality.
• Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy approved for advanced melanoma.

Observation:

• A case study involving a 79-year-old male with advanced melanoma on the left distal thumb.
• The patient elected to undergo T-VEC therapy instead of surgical excision.
• Treatment consisted of 18 sessions of T-VEC administration.

Findings:

• T-VEC therapy demonstrated significant efficacy, leading to complete lesion regression.
• The patient experienced no evidence of melanoma recurrence during long-term follow-up.
• The treatment leveraged T-VEC's dual mechanism of directly killing tumor cells and stimulating an anti-tumor immune response.

Implications:

• This case highlights T-VEC as a viable therapeutic option for advanced melanoma, particularly when surgery is not preferred or feasible.
• Further research is warranted to explore T-VEC's safety profile and potential synergistic effects with other immunotherapies.
• Oncolytic virotherapy represents a promising frontier in the evolving landscape of advanced melanoma treatment strategies.